Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 31.10
+1.05 (3.49%)
Oct 20, 2026, 1:30 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 8.24 billion as of October 20, 2026. It is the 19,512th most valuable company in the world and the 842nd biggest in Taiwan. Its market cap has decreased by 43.86% in one year.
Market Cap
8.24B
Enterprise Value
9.73B
Revenue
657.56M
Global Rank
Country Rank
#842 Taiwan
PE Ratio
n/a
ChartMarket Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 8.24B, a decrease of -50.86%. That is a compound annual growth rate of -6.15%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 20, 2026 | 8.24B | -43.42% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| TCM Biotech International | 9.43B |
| Locus Cell | 8.45B |
| PharmaEngine | 8.13B |
| Acepodia | 7.73B |
| Adimmune | 7.50B |
| Polaris Group | 7.21B |
| OBI Pharma | 6.92B |
| Savior Lifetec | 6.88B |